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BACKGROUND: Companion diagnostics (CD) testing aims to stratify the patient 
population. It conditions the choice of best available therapeutic options, limiting 
targeted therapy (TT) to subgroups most likely to benefit and triggers potential cost 
savings. OBjeCtives: To provide a general framework and a list of key methodo-
logical points to be addressed while conducting a model-based economic evaluation 
of CD-TT pairings, especially in oncology. MethODs: Based on a health economic 
literature review and a clinical expert panel with examples drawn from cases of CD 
testing selection biomarker predictive of the response level towards an anti-cancer 
TT. ResUlts: As CD and TT have embedded values, it is important to assess them 
concomittantly within a shared modeling framework. We propose a decision tree to 
model the patient population stratification and to incorporate impacts of analytical 
and clinical validity. The former refers here to the inability of the CD to accurately 
and reliably inform the biomarker resulting in true (false) positive/negative cases, 
whereas the latter relates to the penetrance, i.e. the strength of association between 
the biomarker and clinical phenotypes (treatment effect). Such parameters are crucial 
especially in cases multiple distinct lab-tests (commercial vs. home-brew, technics, 
amount of informations provided regarding the biomarker). Each patient sub-group 
outcomes are required to be modeled (costs and health effects). A Markov state-tran-
sition model either based on treatment pathway and/or disease staging represents 
both adequate approaches to simulate the clinical outcomes, incorporating specific 
efficacy parameters per sub group depending on their biomarker expression levels. 
In instances, time spent until the CD result delivery exceeds a clinical significant 
threshold, testing delay shall be modelled such as all parameters driving loss of oppo-
runity. CONClUsiONs: Beyond reasonable simple binary-type of selection biomarker, 
more complex types of biomarkers and CD technologies (full sequences) has risen 
additional complexity and poses new methodological challenges.
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OBjeCtives: Quantitative patient preferences are increasingly considered for health 
care policy decisions. The objective of this study is to develop a methodology to 
combine patient preferences with clinical evidence in a multi-criteria framework 
that takes into account uncertainty in both preferences and clinical evidence. The 
methodology will be illustrated with a case on antiretroviral treatments. MethODs: 
Treatments under consideration are eight highly active antiretroviral therapies 
(HAART) recommended for treatment-naïve patients by the National Institute of 
Health. The treatments are compared on the probabilities of virologic failure, hyper-
sensitivity reaction, bone damage, and kidney damage; and on the treatability of 
bone/kidney damage. Preferences from 147 patients were elicited with a discrete 
choice method in an earlier study. Preferences were assumed to be distributed with 
a multivariate normal distribution. Treatment performances as identified from clini-
cal trials were assumed to be distributed with beta distributions. The probability 
distributions around preferences and clinical performances were combined with a 
Monte Carlo simulation method to estimate the joint probability distribution around 
each treatment’s patient-weighted utility. ResUlts: The three treatments with the 
highest mean patient-weighted utility were dolutegravir+abacavir/lamivudine (-0.4, 
95% CI: -1.3 to 0.5), raltegravir+tenofovir/emtricitabine (-0.5, 95% CI: -1.6 to 0.7) and 
darunavir/ritonavir+tenofovir/emtricitabine (-0.6, 95% CI: -2.0 to 0.8). There was con-
siderable overlap between the probability distributions of patient-weighed utilities 
(probability of first rank reversal: 49%; probability of any rank reversal: > 99%). When 
ignoring uncertainty around patient preferences, the probability of a first rank rever-
sal dropped to 12%, and that of any rank reversal dropped to 88%. CONClUsiONs: 
A probabilistic multi-criteria methodology was developed that explicitly combines 
patient preferences and clinical evidence. The individual or joint impact of uncer-
tainty in these on the treatments’ patient-weighted utilities is assessed. Although 
limited by the small number of attributes, the illustrative case suggests the choice 
of HAART is highly sensitive to patient preferences.
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OBjeCtives: Cross-sectional studies showed that, for modelling health-related 
quality of life (HRQoL), beta regression is superior in terms of fit and predictive accu-
racy to other commonly used methods based on normality distribution assumption. 
Although, longitudinal HRQoL measurements are widely used in clinical trials, not 
much is known about beta regression suitability in this context. This is mainly due 
to software unavailability with classical estimation methods. This study proposes 
to model the longitudinal HRQoL outcome using a mixed beta regression estimated 
by Bayesian Markov chain Monte Carlo (MCMC) methods implemented in WinBUGS. 
Compared to the classical approach, not only the Bayesian estimation is consider-
ably easier to implement but has other advantages; for example, the possibility of 
including informative priors, enabling analysts to incorporate multiple sources of 
evidence in a single model. MethODs: We used a 16-year longitudinal follow-up 
for modelling the relationship between SF-6D HRQoL and variables age, gender and 
mortality risk by means of a mixed beta regression. Besides modelling the mean 
tant to identify patients who are most likely to benefit. Doing so using clini-
cal trials is prohibitively expensive; thus a mathematical modeling approach is 
required. MethODs: We developed a framework for stratified cost-effectiveness 
analysis using individual-based discrete-event simulations, consisting of a natu-
ral history component that captures mutation distribution, correlations between 
mutation and other risk factors (e.g. family history), and cancer incidence, progres-
sion and mortality, and a health care process component that captures interac-
tions between the patients and the health care system, through genetic testing, 
screening, diagnosis and treatment, and their costs. The genetic screening strat-
egy consists of 3 steps: a benefit- risk assessment step, in which patients are 
assessed for risk of carrying mutations and potential benefits from genetic testing, 
a genetic testing step, in which qualified patients within an optimal risk bracket 
are given the appropriate tests and an intervention step, in which patients are 
given care based on the results from the genetic tests. ResUlts: We use the fol-
lowing approach to explore and identify optimal strategies for 3 genetic screening 
applications: Dinh et al. demonstrated that primary screening for Lynch syndrome 
in patients at least 25 years old and with a risk of at least 5% was cost effective. 
Folse et al. showed that single-nucleotide polymorphism (SNP) screening for breast 
cancer risk for recommending patients to MRI screening was most cost-effective 
in women age 40 with a lifetime risk of 16 to 28%. Green et al showed that the 
same genetic test for recommending patients to chemoprevention was most cost-
effective for women age 50-59 with a 5-year risk of 1.2-1.66%. CONClUsiONs: As 
more genetic tests becomes available, this method can be used to identify screen-
ing strategies that maximize cost-effectiveness.
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OBjeCtives: To develop a flexible and computationally efficient discrete event 
simulation (DES) model which could be employed in a cost-effectiveness analysis 
comparing the use of PET-CT scans versus current diagnostic procedures for Conn’s 
disease in hypertensive patients. MethODs: Visual Basic was used for the model 
simulation with Microsoft Excel constituting the front-end software. In order to 
ensure a high level of flexibility, individual patients could be assigned a number 
of personal traits and the clinical, cost and utility inputs were easily adjustable. 
Individual diagnostic procedures were programmed in separate modules with the 
aim of simplifying potential modifications to the diagnostic pathway. ResUlts: 
A DES was constructed to evaluate the cost-effectiveness of new treatments based 
on the experience of patients assigned to intervention and comparator arms. 
Patients were considered individually in each arm, using the same background 
mortality. Time, gender and event dependent risk equations enabled efficient model-
ling of endogenous heterogeneity of the population. Continuous time accounting 
allowed for the modelling of competing adverse events and provided a realistic 
representation of patients’ experience. Preliminary results indicate that the 
use of PET-CT scans for the screening of Conn’s syndrome could be cost-effec-
tive. CONClUsiONs: The newly developed model is the first formal attempt to 
evaluate the cost-effectiveness of this alternative screening technique for hyper-
tensive patients who are suspected of suffering from Conn’s disease. The model will 
be further developed to include probabilistic sensitivity analysis and bootstrapping 
in order to evaluate the robustness of the potential results. Evolutionary algorithms 
will be incorporated to define the most optimal solution from the continuous spec-
trum of potential screening strategies. As the model will utilise actual patient level 
data, it could be used by the decision maker to determine the most cost-effective 
diagnostic strategy.
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OBjeCtives: Patients’ experience of OIC may be unstable, with periods of con-
stipation and non-constipation, an observation supported by physician reports. 
There is, however, a lack of quantitative evidence of this experience. Such evidence 
would be valuable to inform development of economic models for OIC treatments. 
The objective of this abstract is to fill this gap utilizing data from two pivotal 
Naloxegol studies, KODIAC 4 and 5, which demonstrated significant improvements 
in SBM frequency response compared to placebo over 12 weeks. MethODs: 892 
non-cancer pain patients with OIC were randomized to Naloxegol 25 mg or pla-
cebo in two pivotal studies. A 4-week rolling determination of OIC and non-OIC 
status at weeks 4 through 12 was used in time-to-event analyses. Patients were 
considered OIC if they reported < 3 SBMs for > = 2 out of the 4 weeks and non-OIC 
if reported > = 3 SBMs for > = 3 out of 4 weeks. Those with non-OIC status at week 
4 were selected as the baseline and first observed OIC status was considered an 
event. Parametric analyses with Exponential, Weibull, Gompertz, Log-normal, Log-
logistic, and Generalized Gamma distributions were conducted. ResUlts: Based 
on the parametric time-to-event analysis results, the Log-normal distribution was 
selected as the best fit and provided plausible long term projections. Naloxegol had 
a noticeable separation for extending the time to first OIC event when compared 
to placebo over the projected long-term follow-up. CONClUsiONs: This research 
demonstrates that the natural fluctuation between OIC and non-OIC is substantial 
and requires integration into an economic model. Even in the absence of treat-
ment, a substantial proportion of patients become non-OIC, and a significant 
proportion of these remain in non-OIC subsequently. Nevertheless, a treatment 
effect for Naloxegol was observed over and above this ‘background’ placebo vari-
ation in the experience of OIC.
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dataset). The models were also tested in a clinical dataset including ordered 
response categories for four different treatments in psoriasis patients. Both fixed 
and random effects models were studied. ResUlts: In the POA dataset, the PO 
fixed effects model had the lowest residual deviance (54.8 versus 58.9 for the ML 
model) and uncertainty of treatment effects (49% lower standard error (SE)). In the 
nPOA dataset, the predictions of the PO model were biased, and the ML model had 
the lowest residual deviance (52.7 versus 271.0 for the PO model). Visual inspection 
indicated a partial violation of the PO assumption in the psoriasis data. Analyses of 
the psoriasis data, showed that the PO fixed effects model had the lowest residual 
deviance (18.1 versus 20.9) and uncertainty (62% lower SE). However, PO model 
predictions were biased for treatment responses which violated the PO assump-
tion. CONClUsiONs: Statistical selection of NMA models for ordered outcomes 
should be based on the PO assumption and deviance measures. If data satisfies the 
PO assumption, the PO model differentiated treatment effects better as a result of 
lower uncertainty. In terms of flexibility, the PO model can handle data from studies 
that use different cut-offs for response categories and the ML model can be applied 
to datasets violating the PO assumption.
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OBjeCtives: The aim of the study was to assess the effect of an immunotherapy 
for the treatment of advanced non–small-cell lung cancer (NSCLC). MethODs: 
Data from a phase III, multicenter, randomized, open-label trial evaluating the 
efficacy of one EGF-based cancer vaccine (CIMAvaxEGF) as switch maintenance in 
patients with advanced NSCLC, were used. Survival analysis using Kaplan Meier 
estimates was performed. Weighted log-rank was conducted to assess the later 
effect of the immunotherapy. Additionally, a finite mixture model to the primary 
endpoint (Overall Survival, OS) was fitted. Weibull distribution was assumed for 
the overall survival and a mixture model consists of one, two or three components 
was fitted.. All analysis was conducted using the NLMIXED procedure in SAS. 
The Akaike Information Criterion (AIC) was used for model selection. ResUlts: 
Intention-to-treat (ITT) analysis showed 1.44 months of OS benefit for vaccinated 
patients with confirmed delayed-separation phenomena (OS: Vaccine arm, 10.37 
months vs. Control arm, 8.93 months; p= 0.043). The mixture model with the best 
goodness to fit to the data consists of two components (AIC= 3097.7). The two 
mixture components represent short-term and long-term survival subpopula-
tions. The proportions of the subpopulations are estimated to be equal to 0.89 
and 0.11 respectively. The median OS was estimated to be equal to 9.59 and 60.32 
for short- and long- term survival populations, respectively. 23.26% and 76.74% 
from the patients who were classified into long-term survival subpopulation were 
from the control and vaccinated group, respectively. From them, 7 (70%) patients 
in the control group and 25 (75%) patients in the treated group were still alive at 
the end of the study. CONClUsiONs: The results confirm that the vaccination 
with CIMAvaxEGF prolongs the survival of the advanced NSCLC patients. Mixture 
models allow assessing the efficacy/effectiveness of vaccines and biological prod-
ucts in the presence of heterogeneous populations.
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OBjeCtives: In the third party funder environment most analyses focus on ret-
rospective claims analyses; the aim of predictive modelling is to estimate future 
claims or current risk, based on the probability of a hospital event using historical 
data. MethODs: A logistic regression approach is followed where the likelihood of 
a hospitalisation event is established and mapped to a cost estimate. The modelling 
process involved establishing a development and validation sample, identifying the 
predictor variables, building and lastly validating the sample. During the model 
building process the development and validation population consisted of 149 416 
and 47623 beneficiaries respectively; where the data was obtained from a third 
party funder consisting of 3 years of data. During the building process the depend-
ant variable (Y= Logg (odds)) takes on the value 1 or 0 depending on whether or not a 
hospital event occurred. To calculate the cost per beneficiary a weighted probability 
was multiplied by the average cost of a hospital authorisation. Beneficiaries were 
classified as high risk if log (odds) > = 0.7. ResUlts: The final model is: Log (odds) 
= -0.11X1+0.00576X2+0.409X3+0.179X4+0.614X5 where X1-X5 denotes the predictor 
variables. X1 denotes an indicator variable for gender, X2 the predictor variable for 
age, X3 the HIV indicator variable, X4 the diabetes indicator variable and X5 the 
chronic indicator variable. The strongest predictors were the chronic indicator vari-
able and age. The validation process resulted in 79% of the beneficiaries being cor-
rectly classified and the cost estimation resulted in totals within 3-5% of the actual 
values. CONClUsiONs: The proposed model predicts hospitalisation efficiently at 
a beneficiary level and can be implemented to monitor risk and the associated cost 
(hospital or total) for individuals, employer group or the third party funder. Third 
party risk management and cost estimation are other applications of the model.
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Joint MoDelling of the Change in tuMoR size anD oveRall suRvival; a 
PaRaMetRiC MoDel ConsiDeRing Patient heteRogeneity not oBseRveD 
at Baseline
Majer I.M., Heeg B.
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parameter, we also modeled the precision parameter using a regression structure. 
Regression coefficients and predictive accuracy from this model estimated using 
the Bayesian approach with vague priors were compared to those from a linear 
mixed effects model estimated classically. ResUlts: Our results indicated that beta 
distribution fitted the SF-6D outcome better than normal distribution. Furthermore, 
compared to the linear mixed effects model, the mixed beta regression model was 
superior in terms of predictive model accuracy. We found that mortality risk had a 
significant effect on both mean and precision parameters: we observed lower mean 
HRQoL for higher mortality risk and higher variation of health utilities for higher 
mortality risk. CONClUsiONs: Mixed beta regression offers a superior approach 
for modelling the HRQoL outcome longitudinally. Furthermore, such a model can 
be easily implemented using freely available Bayesian software.
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OBjeCtives: Parametric survival modeling (PSM) is often used in cost-effectiveness 
analyses of oncology treatments to aid in lifetime projections due to right censor-
ing of data. We sought to better understand the effect of sample sizes and data 
maturity (follow-up time) on PSM projections to aid in the design of clinical tri-
als and the interpretation of cost-effectiveness models. MethODs: We modeled 
overall survival (OS) for advanced colorectal cancer patients treated with first-line 
chemotherapy and/or a biologic using SEER-Medicare data (2004-2010). Survival 
was estimated using Kaplan-Meier (KM) and PSM methods. From the full cohort, we 
randomly drew patients to match typical sample sizes from Phase II and III clinical 
trials (n= 50, 100, 200, and 400). Additionally, arbitrary data cutoffs were created 
to proxy clinical trial follow-up times (t= 3, 6, 9, 12, 24, and 36 months). Using PSM 
methods mean survival from the full cohort was compared with survival from the 
combinations of sample sizes and follow-up times. ResUlts: Using the KM method, 
6% of patients were alive at the end of the follow-up period (6.5 years). Mean OS 
from the full cohort was estimated to be 21.9 months using the PSM method (best 
fit Weibull curve). OS estimates for the sample size and follow-up time combina-
tions ranged from 5.9-28.0 months. Minimum and maximum survival projections 
represented a 73% underestimation and 28% overestimation of survival compared 
with the full cohort projection, respectively. Projection accuracy was improved when 
t≥ 6 months and n≥ 200. CONClUsiONs: Both sample size and data maturity have 
a profound effect on survival projections. Care should be taken when interpreting 
projections in cost-effectiveness models, especially when sample size is low and 
follow-up time short. In addition to power calculations, clinical trial design should 
account for these issues. Additional analyses in other cancer types may provide 
further guidance for optimum trial design.
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OBjeCtives: Approximately 65% of patients diagnosed with hypertension are 
not well controlled and two third of patients need to be treated by two or more 
drugs for achieving target blood pressure. The aim of this study was to describe 
antihypertensive treatment patterns in real life settings by using Markov chain 
model. MethODs: Data concerning prescriptions of patients with diagnosed hyper-
tension were obtained from a large primary care survey conducted in 2012 using 
CSD Longitudinal Patient Database. Patients selected were treated with sartans, 
prescribed alone or in combination with amlodipine and/or hydrochlorothiazide 
(HCT), either in free associations or in fixed combinations. A Markov chain model 
M1 with 4-states (A: single sartan, B: sartan+ amlodipine, C: sartan + HCT, D: sar-
tan + amlodipine + HCT) was proposed to model transitions from one treatment 
to another over time. A second chain, M2, with 6 states was also studied, in which 
dual-therapies were divided into two states depending on whether the combination 
was free or fixed. Age and sex were included as covariates. R packages and MSM 
DIAGRAM were used. ResUlts: 11,976 patients were selected, 49% were men, aged 
69 years on average (SD = 11), suffering from hypertension for 7 years on average, 
35% had diabetes, 5% renal failure and 31% a previous cardiovascular event. At the 
time of selection, the distribution between the states was as follows: A: N = 5187 
(43.3%), B: N = 1060 (8.9%), C: N = 5120 (42.8%), D: N = 609 (5%). At the end of one 
year, > 93% of patients had remained in the same state of M1. The M2 model showed 
substantial transitions from free to fixed associations. Age and sex did not change 
the coefficients. CONClUsiONs: The Markov chains used to visually describe the 
evolution of treatment regimens are useful for analyzing large longitudinal data-
bases of prescriptions.
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MultinoMial logistiC MoDel foR netwoRk Meta-analyses of oRDeReD 
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OBjeCtives: Network meta-analysis (NMA) techniques have been developed to 
study relative treatment effects for several outcome types (e.g. time-to-event out-
comes). No literature exists comparing models of NMA for ordered categorical data, 
though models are available with different characteristics. This study compared 
the proportional odds (PO) and multinomial logistic (ML) model for NMA in ordered 
categorical datasets based on model fit and qualitative characteristics. MethODs: 
To contrast model performance, two extreme datasets were simulated, one which 
exactly satisfied the PO assumption (POA dataset), and one which did not (nPOA 
